Biotechnology Acquisitions in New York

Pfizer Inc. completed the acquisition of clinical-stage biopharmaceutical company Metsera, Inc. for $65.60 per share (approximately $7.0 billion enterprise value) plus contingent value rights of up to $20.65 per share. The deal brings Metsera's obesity and cardiometabolic therapeutic candidates into Pfizer's pipeline and makes Metsera a wholly owned subsidiary headquartered in New York.

The Jackson Laboratory (JAX) has completed its acquisition of the New York Stem Cell Foundation (NYSCF), combining JAX's genetics and preclinical modeling expertise with NYSCF's stem cell automation and high-throughput research platform. The unified nonprofit aims to create an integrated discovery platform that accelerates translational research by linking genomics, stem cell biology, and data/AI capabilities.

SERB Pharmaceuticals completed its acquisition of Y-mAbs Therapeutics following a tender offer and statutory merger, making Y-mAbs a wholly owned subsidiary and delisting it from Nasdaq. The deal adds Y-mAbs' antibody-based oncology assets — including Danyelza (naxitamab-gqgk) — to SERB's rare disease and rare oncology portfolio to expand its commercial capabilities in pediatric and rare cancers.

Battery Ventures has completed a take-private acquisition of Enzo Biochem (Enzo), a life‑science research reagents company. Battery plans to invest in R&D, accelerate growth, and build Enzo into a broader reagents platform through product development and targeted add-on acquisitions.

Granata Bio has acquired Oviva Therapeutics, a women's health biotech developing OVI-586, a first-in-class therapeutic aimed at extending ovarian function and improving reproductive outcomes. The acquisition expands Granata's fertility and women's health pipeline and will advance OVI-586 toward further development for applications including menopause, contraception, and in vitro fertilization (IVF).

AbbVie has completed the acquisition of clinical-stage biopharmaceutical company Landos Biopharma, adding Landos’ lead investigational asset NX-13 — an oral NLRX1 agonist in Phase 2 for ulcerative colitis — to AbbVie’s immunology pipeline. The deal was valued at $20.42 per share plus contingent value rights tied to a clinical milestone and will take Landos private, with Landos common stock ceasing NASDAQ trading prior to May 24, 2024.

Nuvation Bio Inc. completed an all-stock acquisition of AnHeart Therapeutics Ltd., making AnHeart a wholly owned subsidiary and transforming Nuvation into a late-stage global oncology company. As part of the transaction AnHeart securityholders received Nuvation Bio common stock, convertible preferred stock and warrants, and AnHeart executives and investors joined Nuvation's board.

Eli Lilly has entered into a definitive agreement to acquire Versanis Bio, a private clinical-stage biopharmaceutical company developing bimagrumab for cardiometabolic diseases and obesity. The deal could deliver up to $1.925 billion to Versanis shareholders and is intended to combine Versanis’ activin/myostatin biology expertise with Lilly’s incretin portfolio to advance combination treatments for obesity and related cardiometabolic conditions.

Biocare Medical, a GHO Capital-backed provider of automated IHC and FISH instrumentation and reagents, has acquired Empire Genomics, a designer and manufacturer of FISH/CISH probes and molecular biomarkers. The deal expands Biocare's molecular portfolio (bringing over one million biomarkers) and adds rapid biomarker development capabilities to accelerate cancer research and diagnostics.

Kriya Therapeutics has acquired Redpin Therapeutics, a preclinical New York City–based gene therapy company with a proprietary chemogenetics platform. The deal establishes Kriya's neurology therapeutic-area portfolio by adding Redpin’s lead programs targeting epilepsy and trigeminal neuralgia, and brings chemogenetic capability to Kriya’s gene therapy engine.

Avista Capital Partners has acquired Taconic Biosciences from H.I.G. Capital. Taconic, a Rensselaer, New York–based provider of genetically engineered murine research models and related preclinical services, will leverage Avista's healthcare investing expertise to pursue organic growth and strategic acquisitions in the GEMs market.

Kindbody has acquired Phosphorus Labs, a preventative genomics and clinical genetic-testing company, including Phosphorus’s 8,000 sq. ft. reference laboratory in Secaucus, New Jersey. The acquisition brings genetic testing and carrier screening capabilities in-house as Kindbody creates its KindLabs division to integrate diagnostics into its end-to-end fertility and family-building care.

Valo Health has acquired TARA Biosystems, a New York City–based company specializing in human 3D tissue engineering and cardiac disease modeling, to create an integrated cardiovascular drug discovery and development platform. The deal combines TARA's in vitro cardiac models with Valo's Opal computational platform to expand Valo's capabilities in cardiovascular drug discovery and accelerate development of new therapies.

Zymergen Inc. acquired Lodo Therapeutics Corporation from Accelerator Life Science Partners (ALSP), integrating Lodo’s metagenomic natural‑product discovery platform into Zymergen’s technology stack. ALSP had been an investor and operator of Lodo following a $17 million Series A and a collaboration with Genentech; the financial terms of the deal were not disclosed by ALSP in its announcement.

Roivant Sciences entered into a definitive business combination agreement with Montes Archimedes Acquisition Corp. (MAAC), a SPAC sponsored by Patient Square Capital, to take Roivant public on Nasdaq under the ticker ROIV. The transaction is expected to provide up to $611 million of gross proceeds (including a $200 million PIPE) to fund discovery and development programs and extend Roivant's operating runway through mid-2024.

Welsh, Carson, Anderson & Stowe (WCAS) committed up to $250 million to a strategic partnership with newly-formed Kiniciti, a platform that will invest in non-therapeutic companies supporting the cell and gene therapy ecosystem. The capital will support Kiniciti's flexible investment model (control, growth equity and significant minority stakes) to scale companies that provide process, production, materials and delivery capabilities for CGT.

GTCR’s portfolio company Cole-Parmer has acquired ZeptoMetrix, a Buffalo-based developer and manufacturer of quality control standards and verification panels for molecular diagnostic testing. The acquisition expands Cole-Parmer’s life sciences quality controls and reference standards portfolio and strengthens its capabilities in infectious disease and molecular diagnostics.

Eli Lilly agreed to acquire Prevail Therapeutics for $22.50 per share in cash (approximately $880 million) plus a non-tradable contingent value right (CVR) worth up to $4.00 per share (up to ~$160 million), for total consideration of up to ~$1.04 billion. The deal establishes a gene therapy program at Lilly anchored by Prevail’s AAV9-based neuroscience pipeline; the transaction was structured as a tender offer with expected close in Q1 2021 subject to customary conditions.

Sana Biotechnology announced the acquisition of Oscine Corp., integrating Oscine’s glial progenitor cell program and technologies into Sana’s broader platform to advance CNS therapies. Steve Goldman, Oscine’s scientific founder, joined Sana as Head of CNS Therapy; terms of the acquisition were not disclosed.

ATAI Life Sciences AG acquired a majority stake in New York–based pharmaceutical company Kures to advance Kures' mitragynine-derived therapeutic candidates (KUR-101 and KUR-002) targeting pain and opioid use disorder. The deal brings Kures onto ATAI's biotech platform and appoints ATAI CSO Srinivas Rao as Kures CEO to accelerate development and integrate the assets into ATAI's mental-health-focused pipeline.

Repligen Corporation agreed to acquire Engineered Molding Technology (EMT), an Albany, New York manufacturer of single-use silicone assemblies, connectors and tubing used in biologic drug manufacturing. The purchase expands Repligen’s single-use ProConnex flow-path capabilities, streamlines its supply chain for ATF, and aims to deliver faster lead-times and a more integrated offering for biopharma and CDMO customers; terms were not disclosed and the deal was expected to close in Q3 2020.

L2P Research, LLC has acquired METIS Research Laboratories, a Ronkonkoma, New York-based preclinical CRO that provides radiotracer, radioligand binding, ADME/PK and QWBA services. The acquisition adds a GLP-compliant 5,000 sq. ft. facility and expands L2P's preclinical capabilities for pharma, biotech and academic customers.